Table 5.
Overall Survival (OS), Progression Free Survival (PFS) and Time to Treatment Failure (TTF) in KRAS negative, borderline and positive patients at Progressive Disease (PD).
| KRAS | N° | mOS (m) | CI95% (m) | P-value |
|---|---|---|---|---|
| Negative | 75 | 36 | 28.5-43.5 | |
| Borderline | 28 | 48 | 23.2-72.8 | <0.001 |
| Positive | 3 | 6 | 2.8-9-2 | |
| KRAS | N° | mPFS (m) | CI95% (m) | P-value |
| Negative | 75 | 20 | 12-6-27-4 | |
| Borderline | 28 | 16 | 10-2-21-8 | <0.001 |
| Positive | 3 | 5 | 5-0-5-0 | |
| KRAS | N° | mTTF (m) | CI95% (m) | P-value |
| Negative | 75 | 22 | 11-5-32-5 | |
| Borderline | 28 | 25 | 14-9-35-1 | <0.001 |
| Positive | 3 | 5 | 3.4-6.6 |
mOS, median Overall Survival; mPFS, median Progression Free Survival.
mTTF, median Time To Failure treatment; m, months.